Kane says antimicrobial compound superior to standard assay

By Elaine Rigoli

Tampa, Fla., Aug. 3 - Kane Biotech, Inc. said the results of a study published in the journal Antimicrobial Agents and Chemotherapy showed that its compound, when coated on urinary catheters, is superior in terms of sensitivity and specificity when compared to the current standard assay.

Kane said the compound in this study was one of several candidate products that came out of the company's research program to develop and screen novel products with antibiofilm activity.

This research program yielded the discovery of KBI-5898, the company's lead product for the antimicrobial coating of urinary catheters, according to a news release.

In November 2005, Kane Biotech announced the results of an in-vivo study in which KBI-5898-coated urinary catheters were shown to be significantly less likely to be colonized by bacteria than either currently marketed silver-hydrogel coated catheters or uncoated catheters.

The study further showed that KBI-5898 coated urinary catheters were also significantly less likely to cause catheter-related infections than either the silver-hydrogel coated or uncoated catheters.

Kane is a biotechnology company based in Winnipeg, Manitoba.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.